Novo Nordisk releases 2025 annual report

Novo Nordisk A/S has issued its annual report for 2025.

Accepted by SEC EDGAR 02/05/2026 - 02:54 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Novo Nordisk A/S has issued its annual report for 2025. The report is available on the company’s investor website and is also attached in iXBRL format for electronic analysis.

Novo Nordisk is a global healthcare company founded in 1923 and headquartered in Denmark. It focuses on defeating serious chronic diseases, with a heritage in diabetes and efforts to pioneer scientific breakthroughs, expand access to medicines, and work toward prevention and cures.

The company employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares trade on Nasdaq Copenhagen, and its American depositary receipts trade on the New York Stock Exchange under the symbol NVO.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Novo Nordisk (NONOF) announce in this 6-K filing?

Novo Nordisk announced it has issued its annual report for 2025. The report is available on its investor website and attached in iXBRL format, giving investors structured digital access to the full-year information and disclosures.

Where can investors access Novo Nordisk (NONOF) 2025 annual report?

Investors can access Novo Nordisk’s 2025 annual report on its investor website at novonordisk.com under the annual report section. The report is also attached in iXBRL format for easier digital review and data extraction.

What kind of company is Novo Nordisk (NONOF)?

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. It focuses on defeating serious chronic diseases, building on its diabetes heritage, through scientific innovation, broader access to medicines, and efforts in prevention and potential cures.

How large is Novo Nordisk’s (NONOF) global footprint?

Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. This broad footprint highlights its significant international presence in treating serious chronic diseases worldwide.

On which exchanges are Novo Nordisk shares listed?

Novo Nordisk’s B shares are listed on Nasdaq Copenhagen under Novo-B. Its American depositary receipts (ADRs) are listed on the New York Stock Exchange under the symbol NVO, providing access to both European and U.S. investors.

How can investors and media contact Novo Nordisk (NONOF)?

Media can contact Novo Nordisk via named media representatives and the globalmedia@novonordisk.com email. Investors can reach the investor relations team through listed contacts and emails, including nvno@novonordisk.com, along with various dedicated phone numbers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________

FORM 6-K

________________

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

February 4, 2026

________________

NOVO NORDISK A/S

 (Exact name of Registrant as specified in its charter)

Novo Allé 1

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒           Form 40-F ☐

 

 

Novo Nordisk has published its annual report for 2025

Bagsværd, Denmark, 4 February 2026 – Today, Novo Nordisk A/S has issued its 2025 annual report.

The report is available here: https://www.novonordisk.com/investors/annual-report.html and is attached in iXBRL format.

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Page 2 of 2

Contacts for further information:

Novo Nordisk Media:
Ambre James-Brown	Liz Skrbkova (US)
+45 3079 9289	+1 609 917 0632
globalmedia@novonordisk.com	lzsk@novonordisk.com
Novo Nordisk Investors:
Michael Novod	Jacob Martin Wiborg Rode
+45 3075 6050	+45 3075 5956
nvno@novonordisk.com	jrde@novonordisk.com
Sina Meyer	Max Ung
+45 3079 6656	+45 3077 6414
azey@novonordisk.com	mxun@novonordisk.com
Christoffer Sho Togo Tullin	Alex Bruce
+45 3079 1471	+45 3444 2613
cftu@novonordisk.com	axeu@novonordisk.com
Frederik Taylor Pitter
+1 609 613 0568
fptr@novonordisk.com

Attachments

· NOVO-2025-12-31-1-en (https://ml-eu.globenewswire.com/Resource/Download/b3a9153e-1c61-46d4-86c3-18e7aeac204e)

Novo Nordisk A/S Investor Relations	Novo Allé 1 2880 Bagsværd Denmark	Telephone: +45 4444 8888	Internet: www.novonordisk.com CVR no: 24 25 67 90
			Company announcement No 05 / 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: February 4, 2026   NOVO NORDISK A/S   Maziar Mike Doustdar Chief Executive Officer